Foresite Capital Management IV, LLC — Q2 2024 13F-HR

← Foresite Capital Management IV, LLC

Q2 2024 · 13F-HR

Foresite Capital Management IV, LLCholdings as filed

Filed 2024-08-13 · accession 0001104659-24-088863

$148.8M

Reported value

Positions

2024-06-30

Period end

View analyzed profile →PRO

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
N69605108	PHVS	Pharvaris N.V.	$80.7M	54.2%	4,293,854	Common	SOLE
50127T109	KURA	Kura Oncology, Inc.	$38.1M	25.6%	1,849,947	Common	SOLE
87164F105	SNDX	Syndax Pharmaceuticals, Inc.	$18.0M	12.1%	875,000	Common	SOLE
55083R104	—	Lyell Immunopharma, Inc.	$12.1M	8.11%	8,325,000	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.